Individual generic drug information

bicalutamide

Reference monograph

Part of registered formulation

BICALUTAMIDE

Reference record: Bicalutamide
Source: BNF 80 (2020–2021)
Printed source pages: 1021
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Bicalutamide only.

Indications And Dose

Locally advanced prostate cancer at high risk of disease progression either alone or as adjuvant treatment to prostatectomy or radiotherapy | Locally advanced, non- metastatic prostate cancer when surgical castration or other medical intervention inappropriate ▶BY MOUTH ▶Adult: 150 mg once daily Advanced prostate cancer, in combination with gonadorelin analogue or surgical castration ▶BY MOUTH ▶Adult: 50 mg once daily, to be started at the same time as surgical castration or at least 3 days before gonadorelin therapy Prostate cancer (metastatic) with the aim of retaining sexual function. ▶BY MOUTH ▶Adult: 150 mg once daily l UNLICENSED USE g Bicalutamide is used in prostate cancer (metastatic) with the aim of retaining sexual function, h but it is not licensed for this indication.

Source page 1021

Cautions

Risk of photosensitivity—avoid excessive exposure to UV light and sunlight

Source page 1021

Safety

Extracted information for Bicalutamide only.

Interactions

→Appendix 1: bicalutamide

Source page 1021

Side Effects

▶Common or very common Alopecia. anaemia. appetite decreased. asthenia. breast tenderness. chest pain. constipation. depression. dizziness. drowsiness. ﬂatulence. gastrointestinal discomfort. gynaecomastia. haematuria. hair changes. hepatic disorders. hot ﬂush. hypertransaminasaemia. nausea. oedema. sexual dysfunction. skin reactions. weight increased ▶Uncommon Angioedema. interstitial lung disease ▶Rare or very rare Photosensitivity reaction ▶Frequency not known QT interval prolongation

Source page 1021

Hepatic Impairment

Manufacturer advises caution in moderate to severe impairment (increased risk of accumulation).

Source page 1021

Monitoring Requirements

Consider periodic liver function tests.

Source page 1021

Dose and formulations

Extracted information for Bicalutamide only.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension Tablet ▶Bicalutamide (Non-proprietary) Bicalutamide 50 mg Bicalutamide 50mg tablets | 28 tablet P £95.83 DT = £4.00 Bicalutamide 150 mg Bicalutamide 150mg tablets | 28 tablet P £192.00 DT = £6.66 ▶Casodex (AstraZeneca UK Ltd) Bicalutamide 50 mg Casodex 50mg tablets | 28 tablet P £119.79 DT = £4.00 Bicalutamide 150 mg Casodex 150mg tablets | 28 tablet P £240.00 DT = £6.66

Source page 1021

Clinical care

Extracted information for Bicalutamide only.

Patient And Carer Advice

Risk of photosensitivity Patients should be advised to consider the use of sunscreen.

Source page 1021

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

150 mg once daily

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1021

Adults

First line only; read the complete Indications and dose section above.

50 mg once daily, to be started at the same time

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1021

Adults

First line only; read the complete Indications and dose section above.

150 mg once daily

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1021

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

bicalutamide

Reference monograph

Part of registered formulation

BICALUTAMIDE

Reference record: Bicalutamide
Source: BNF 80 (2020–2021)
Printed source pages: 1021
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Bicalutamide only.

Indications And Dose

Source page 1021

Cautions

Risk of photosensitivity—avoid excessive exposure to UV light and sunlight

Source page 1021

Safety

Extracted information for Bicalutamide only.

Interactions

→Appendix 1: bicalutamide

Source page 1021

Side Effects

Source page 1021

Hepatic Impairment

Manufacturer advises caution in moderate to severe impairment (increased risk of accumulation).

Source page 1021

Monitoring Requirements

Consider periodic liver function tests.

Source page 1021

Dose and formulations

Extracted information for Bicalutamide only.

Medicinal Forms

Source page 1021

Clinical care

Extracted information for Bicalutamide only.

Patient And Carer Advice

Risk of photosensitivity Patients should be advised to consider the use of sunscreen.

Source page 1021

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

150 mg once daily

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1021

Adults

First line only; read the complete Indications and dose section above.

50 mg once daily, to be started at the same time

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1021

Adults

First line only; read the complete Indications and dose section above.

150 mg once daily

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1021

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.